VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer

Key Points

• This trial aims to evaluate the effectiveness of gedatolisib combined with fulvestrant in advanced breast cancer patients.
• Phase trial design
• Investigates the combination of gedatolisib and fulvestrant
• Includes an evaluation with or without palbociclib
• Population comprises patients with hormone receptor-positive, HER2-negative, PIK3CA wild-type advanced breast cancer
• Gedatolisib plus fulvestrant significantly decreased the risk of disease progression or death.
• The outcomes were better regardless of whether palbociclib was included.

Abstract